Corporate partners of the EDF have been asked to contribute towards this work. GlaxoSmithKline plc. (GSK) and Meda AB have contributed funding for the development of the European evidence-based (S3) guideline for the treatment of acne (update 2016) through an educational grant to the EDF. Sponsors had no influence on the content of the guideline. Support was given independent of any influence on methods or results. Sponsors did not receive any information about methods, group members or likely results. The sources of the funding were not known to the experts of the guideline and were not disclosed before the finalization of the guideline. This is a short summary of the complete version of the S3 European Acne guideline, please see online appendix for full text (Document S1. Long Version) and detailed methods report (DOI: 10.1111/jdv.13783). Expiry date: 31 December 2020 MethodsIn order to weight the different recommendations, the group assigned a 'strength of recommendation'. It considered all aspects of the treatment decision, such as efficacy, safety, patient preference and the reliability of the existing body of evidence. Strength of recommendationIn order to grade the recommendation a "standardized guideline" language was used:

Scientific advances are continually improving the knowledge of acne and contributing to the refinement of treatment options; it is important for clinicians to regularly update their practice patterns to reflect current standards. The Global Alliance to Improve Outcomes in Acne is an international group of dermatologists with an interest in acne research and education that has been meeting regularly since 2001. As a group, we have continuously evaluated the literature on acne. This supplement focuses on providing relevant clinical guidance to health care practitioners managing patients with acne, with an emphasis on areas where the evidence base may be sparse or need interpretation for daily practice.

effective for urticaria. Medications that modulate neurologic function, including gabapentin, are effective for recalcitrant pruritus and less sedating than oral antihistamines.2 Treatment of comorbid depression or anxiety can also improve the symptoms and burden of pruritus.Patients without a dermatologic, neurologic, or psychiatric cause for pruritus should be asked about the presence of fevers, chills, night sweats, and/or unintended weight loss, as well as undergoing a full review of systems to assess for localizing symptoms. Physical examination would include palpation of the lymph nodes, spleen, and liver. Testing for a metabolic or neoplastic source of pruritus should be considered for patients with chronic, generalized pruritus who lack a primary skin disease.3 Systemic evaluation of these patients can include malignant neoplasm and thyroid, renal, hepatic, and infectious diseases. 4 Thus, it is important to remember the association of chronic pruritus and internal systemic diseases but to limit screening to the patients without recognizable skin disease. LESS IS MORE Competing Mortality in Cancer Screening A Teachable Moment Story From the Front LinesA 70-year-old man saw his primary care clinician and ex pressed concern about his lung cancer risk after learning a friend had recently died of it. The patient had had an 80-pack-year history, and had quit 7 years previously. His physician ordered a screening chest computed tomographic (CT) scan, which demonstrated a spiculated 12-mm lung nodule that was new when compared with scans done previously for other reasons. This prompted a positron emission tomographic scan, which showed metabolic activity, raising the suspicion for lung cancer. He was referred to a pulmonary-nodule clinic. The man presented to the pulmonary clinic in a wheel chair while receiving continuous oxygen. His medical history revealed severe diastolic heart failure; chronic obstructive pulmonary disease; obesity (his body mass index, calculated as weight in kilograms divided by height in meters squared, was 54); diabetes mellitus with microvascular complications, including stage III chronic kidney disease; and peripheral neuropathy. Additional medical history included several recent falls attributed to progressive neuropathy and deconditioning. These considerations were discussed with the patient and ultimately, invasive diagnostic testing was discouraged. A conservative plan that included a repeated CT scan in 4 months was mutually agreed on. Two months after this visit, the patient was admitted and treated for pneumonia. While recovering in the hospital, his primary team noted that this nodule had not undergone workup and he had another CT scan, which demonstrated interval growth. He was scheduled for an outpatient CT-guided biopsy.Prior to the biopsy, the patient was rehospitalized for pneumonia, this time requiring intensive care unit admission. His medical history was addressed at a multidisciplinary thoracic tumor conference. He was not a surgical candidate, and attempts to biopsy...

ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes highquality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times.